Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy

Inclusion Criteria: * Patients with PCV associated with PED near the polypoidal lesion recently diagnosed, documented by FA, ICGA and OCT. * Visual acuity between 20/40 and 20/400. * Patients older than 50 years (both genders). * Women must be postmenopausal for at least 12 months or surgically sterile. * No previous treatment in the study eye. * Accept and sign the informed consent. * No condition that prevents the monitoring of the patient for one year. * Transparent ocular media and adequate pupillary dilation to allow good images of the fundus. Exclusion Criteria: * Blepharitis or external eye infection. * Allergy to ranibizumab, verteporfin, triamcinolone, fluorescein or indocyanine green. * Patients unable to provide informed consent. * Concomitant ocular disease that impairs visual acuity. * Any intraocular condition (such as cataract or Proliferative Diabetic Retinopathy) in the study eye, in the opinion of the investigator, could require surgery or medication during the follow-up (1 year). * Active intraocular inflammation. * Patients with Glaucoma and with ocular hypertension (IOP \> 25mmHg). * Premenopausal women. Pregnancy or lactation. * Effective treatment for active systemic infection or history of recurrent infection. * Evidence of concomitant disease (cardiovascular, neurological, pulmonary, renal, hepatic, endocrine or gastrointestinal) uncontrolled.